Thank you, and in my biotech experience, FDA usual
Post# of 148183
Quote:
VANCOUVER, Washington, June 08, 2020 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company", a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today the U.S. Food and Drug Administration (FDA) advised the Company, subject to its ongoing review, it could receive its “PDUFA date” on July 10, 2020.
Read More: https://investorshangout.com/post/newpost/605...z6RnUlSehD